High-flow oxygen ‘of no benefit’ in most ACS cases
But for patients who are hypoxic, and for STEMI patients it may be useful, experts say
Most patients with suspected acute coronary syndrome (ACS) don’t have better 30-day mortality outcomes when they receive high-flow oxygen, researchers say.
In the trial conducted in New Zealand 40,872 patients with suspected or confirmed ACS episodes were randomised either to receive high-flow oxygen irrespective of SpO2 (6-8L/min by face mask or 4L/min by nasal cannula) or to a low-flow oxygen protocol.